Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. (October 2019)

• Record Type: Journal Article
• Authors: Eberhardt, Kirsten Alexandra; Mischlinger, Johannes; Jordan, Sabine; Groger, Mirjam; Günther, Stephan; Ramharter, Michael
• Is Part Of: International journal of infectious diseases. Volume 87(2019)
• Page Start: 15
• Page End: 20
• Publication Date: 2019-10
• Subjects: Lassa fever -- Ribavirin -- Haemorrhagic fever -- LASV; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2019.07.015
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: The quality of evidence for the use of ribavirin is very low, stemming largely from a single non-randomized clinical trial with historic controls and high risk of bias. Based on this trial patients with severe Lassa fever seem to benefit from ribavirin treatment. Treatment of mild Lassa fever may lead to an increase in mortality. Re-assessment of ribavirin in the treatment of Lassa fever is urgently required. Abstract: Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this recommendation has been questioned recently. Methods: We conducted a systematic review and included 6 studies providing efficacy data of ribavirin treatment for LF (PROSPERO protocol CRD42018103994). Results: Besides retrospective case series, the evidence mostly relies on a single prospective clinical trial with critical risk of bias. In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23–0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07–5.25). Conclusions: Based on the available data, current treatment guidelines may therefore put patients with mild LF at increased risk of death. The role of ribavirin in the treatment of LF requires urgent reassessment.